Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm

Acute lymphoblastic leukaemia in 2017: Immunotherapy for ALL takes the world by storm, Published online: 19 December 2017; doi:10.1038/nrclinonc.2017.176

In 2017, three groundbreaking immunotherapies for relapsed and/or refractory B-cell acute lymphoblastic leukaemia (ALL) were approved based on impressive outcomes observed in clinical trials. Additional breakthroughs included seminal research into ALL genomics and the importance of adherence to chemotherapy, which will have direct implications for clinical care.

中文翻译：

---

2017年急性淋巴细胞白血病：全民免疫疗法席卷全球

2017年急性淋巴细胞白血病：全民免疫疗法席卷全球

2017年急性淋巴细胞白血病：所有人的免疫疗法席卷全球，在线发布：2017年12月19日；doi：10.1038 / nrclinonc.2017.176

2017年，根据临床试验中观察到的令人印象深刻的结果，批准了针对复发性和/或难治性B细胞急性淋巴细胞白血病（ALL）的三种突破性免疫疗法。其他突破包括对ALL基因组学的开创性研究以及坚持化疗的重要性，这将对临床护理产生直接影响。